[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201505631PA - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
SG11201505631PA
SG11201505631PA SG11201505631PA SG11201505631PA SG11201505631PA SG 11201505631P A SG11201505631P A SG 11201505631PA SG 11201505631P A SG11201505631P A SG 11201505631PA SG 11201505631P A SG11201505631P A SG 11201505631PA SG 11201505631P A SG11201505631P A SG 11201505631PA
Authority
SG
Singapore
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
SG11201505631PA
Inventor
Bernard Christophe Barlaam
David Berry
Benedicte Delouvrie
Craig Steven Harris
Der Brempt Christine Marie Paul Lambert-Van
Gilles Ouvry
Gary Patrick Reid
Gary Peter Tomkinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201505631PA publication Critical patent/SG11201505631PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201505631PA 2013-01-23 2014-01-22 Chemical compounds SG11201505631PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23
PCT/GB2014/050163 WO2014114928A1 (en) 2013-01-23 2014-01-22 Chemical compounds

Publications (1)

Publication Number Publication Date
SG11201505631PA true SG11201505631PA (en) 2015-08-28

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505631PA SG11201505631PA (en) 2013-01-23 2014-01-22 Chemical compounds

Country Status (27)

Country Link
US (2) US9156831B2 (en)
EP (1) EP2948447B1 (en)
JP (1) JP6307096B2 (en)
KR (1) KR102202516B1 (en)
CN (1) CN104936953B (en)
AP (1) AP2015008604A0 (en)
AR (1) AR094553A1 (en)
AU (1) AU2014208964B2 (en)
BR (1) BR112015017331B1 (en)
CA (1) CA2897279C (en)
CL (1) CL2015002027A1 (en)
CR (1) CR20150367A (en)
DO (1) DOP2015000170A (en)
ES (1) ES2608395T3 (en)
HK (1) HK1214592A1 (en)
IL (1) IL239890A0 (en)
MA (1) MA38287B1 (en)
MX (1) MX361136B (en)
NI (1) NI201500096A (en)
PE (1) PE20151979A1 (en)
PH (1) PH12015501584A1 (en)
RU (1) RU2644769C2 (en)
SG (1) SG11201505631PA (en)
TN (1) TN2015000313A1 (en)
TW (1) TWI606047B (en)
UY (1) UY35275A (en)
WO (1) WO2014114928A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
TW201726140A (en) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 Novel biomarkers and methods of treating cancer
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
CN107137405A (en) * 2017-04-14 2017-09-08 黄德莲 A kind of pharmaceutical composition for treating ephritis
CN110317190A (en) * 2018-03-28 2019-10-11 首都医科大学 A kind of application of triazole-ramification of carboxylic esters in field of medicaments
US20210403462A1 (en) 2018-11-05 2021-12-30 Syngenta Participations Ag Pesticidally active azole-amide compounds
CA3118493A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
US20220167618A1 (en) 2019-03-08 2022-06-02 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
CN113597424A (en) 2019-03-20 2021-11-02 先正达农作物保护股份公司 Pesticidally active azoleamide compounds
EP3941914A1 (en) 2019-03-22 2022-01-26 Syngenta Crop Protection AG N-[1-(5-bromo-2-pyrimidin-2-yl-1,2,4-triazol-3-yl)ethyl]-2-cyclopropyl-6-(trifluoromethyl)pyridine-4-carboxamide derivatives and related compounds as insecticides
CA3179912A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Pharmaceutical formulations

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (en) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3028168B2 (en) 1993-03-29 2000-04-04 住化ファインケム株式会社 Method for producing benzenesulfonamide derivative
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
WO1996023783A1 (en) 1995-02-02 1996-08-08 Smithkline Beecham Plc Indole derivatives as 5-ht receptor antagonist
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
WO1998004560A1 (en) 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
WO2002006271A1 (en) 2000-07-19 2002-01-24 F. Hoffmann-La Roche Ag Pyrimidine derivatives
AU2002343557A1 (en) 2001-11-21 2003-06-10 Pharmacia And Upjohn Company Substituted aryl 1,4-pyrazine derivatives
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
WO2004084813A2 (en) 2003-03-21 2004-10-07 Smithkline Beecham Corporation Chemical compounds
DE10348044A1 (en) 2003-10-15 2005-05-19 Imtm Gmbh Dual alanyl aminopeptidase and dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
MXPA06007640A (en) 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Selective kinase inhibitors.
ATE458730T1 (en) 2004-04-13 2010-03-15 Icagen Inc POLYCYCLIC PYRAZINE AS POTASSIUM ION CHANNEL MODULATORS
JP2006028056A (en) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd Pyrimidine derivative and pest controlling agent containing the same
DE602005014786D1 (en) 2004-07-26 2009-07-16 Lilly Co Eli OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR ACTIVITIES, THEIR PREPARATION AND THERAPEUTIC USES
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
RU2008141761A (en) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) C-MET PROTEINKINASE INHIBITORS
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
JP5599610B2 (en) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Treatment of neurodegenerative diseases by inhibition of Hsp90
CL2007002123A1 (en) 2006-07-21 2008-06-13 Irm Llc COMPOUNDS DERIVED FROM HETEROARIL-1H-PIRAZOL, USEFUL AS MODULATORS OF THE DEVELOPMENT AND FUNCTION OF THE LYMPHOCYTES B.
PT2057156T (en) 2006-08-23 2017-05-04 Kudos Pharm Ltd 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008108448A1 (en) 2007-03-07 2008-09-12 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pest control agent
SI2188291T1 (en) 2007-08-14 2013-01-31 Bayer Intellectual Property Gmbh Fused bicyclic pyrimidines
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
UY31384A1 (en) 2007-10-11 2009-05-29 NEW HETEROCICLIC COMPOUNDS FOR THE INHIBITION OF PROTEIN KINASE B
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US8268754B2 (en) 2007-12-07 2012-09-18 Nissan Chemical Industries, Ltd. Substituted dihydroazole compound and pest control agent
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
CN101939319A (en) 2007-12-20 2011-01-05 诺瓦提斯公司 Bis-thiazole derivatives, process for their preparation and their use as medicaments
US20110105500A1 (en) * 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
EP2342190A1 (en) 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
JP2010083883A (en) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
UA104147C2 (en) 2008-09-10 2014-01-10 Новартис Аг Pyrrolidine dicarboxylic acid derivative and use thereof in the treatment of proliferative diseases
JP2010063863A (en) 2008-09-11 2010-03-25 Mugen:Kk Golf practice club indicating hitting point position which has a plurality of pipes or flat plates with different acoustic vibration on back of face portion of head, and method of manufacturing the same
CN101676271B (en) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 Tetracycline derivatives containing unsaturated heterocyclic amine
WO2010054398A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2356113B1 (en) * 2008-11-14 2015-01-07 Bayer Intellectual Property GmbH Heterocyclically substituted aryl compounds as hif inhibitors
KR101755216B1 (en) * 2008-12-19 2017-07-07 버텍스 파마슈티칼스 인코포레이티드 Pyrazine derivatives useful as inhibitors of ATR kinase
CN102264737A (en) 2008-12-23 2011-11-30 雅培制药有限公司 Anti-viral compounds
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
CA2752114C (en) * 2009-02-13 2017-06-20 Bayer Pharma Aktiengesellschaft Fused pyrimidines as akt inhibitors
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011025690A1 (en) 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
EP2491039A1 (en) 2009-10-20 2012-08-29 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011089400A1 (en) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibitors of pi3 kinase
BR112012018954A2 (en) 2010-02-05 2016-04-12 Merck Patent Gmbh hetaryl- [1,8] naphthyridine derivatives
JP2011178673A (en) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd Control method for non-agricultural/horticultural insect pest
CN104940200B (en) 2010-03-30 2019-06-28 维颂公司 Inhibitor of the polysubstituted aromatic compounds as fibrin ferment
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
RU2012153675A (en) 2010-05-12 2014-06-20 Вертекс Фармасьютикалз Инкорпорейтед COMPOUNDS USED AS ATR KINASE INHIBITORS
CN102311396B (en) 2010-07-05 2015-01-07 暨南大学 Pyrazine derivative and preparation method as well as application thereof to pharmacy
TWI617560B (en) * 2010-09-14 2018-03-11 伊塞利克斯公司 Inhibitors of pi3k-delta and methods of their use and manufacture
CA2810708A1 (en) * 2010-09-16 2012-03-22 Hutchison Medipharma Limited Fused heteroaryls and their uses
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN102718745A (en) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 Novel amino pyridine compound, its preparation method, pharmaceutical composition containing compound and application thereof
WO2012162635A1 (en) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
WO2013049591A2 (en) 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof

Also Published As

Publication number Publication date
CN104936953B (en) 2017-03-08
KR102202516B1 (en) 2021-01-12
NI201500096A (en) 2016-02-16
RU2644769C2 (en) 2018-02-14
IL239890A0 (en) 2015-08-31
ES2608395T3 (en) 2017-04-10
EP2948447B1 (en) 2016-09-21
JP6307096B2 (en) 2018-04-04
CR20150367A (en) 2015-10-20
TW201522329A (en) 2015-06-16
CL2015002027A1 (en) 2015-11-13
CA2897279A1 (en) 2014-07-31
AU2014208964A1 (en) 2015-08-06
DOP2015000170A (en) 2015-08-16
US9156831B2 (en) 2015-10-13
KR20150109385A (en) 2015-10-01
MA38287B1 (en) 2018-08-31
PH12015501584A1 (en) 2015-10-05
CA2897279C (en) 2020-12-29
TN2015000313A1 (en) 2017-01-03
RU2015132370A (en) 2017-03-02
AU2014208964B2 (en) 2016-09-01
UY35275A (en) 2014-07-31
TWI606047B (en) 2017-11-21
MX361136B (en) 2018-11-28
US20140206700A1 (en) 2014-07-24
BR112015017331B1 (en) 2022-01-11
MA38287A1 (en) 2018-01-31
JP2016508484A (en) 2016-03-22
EP2948447A1 (en) 2015-12-02
WO2014114928A1 (en) 2014-07-31
AP2015008604A0 (en) 2015-07-31
PE20151979A1 (en) 2016-01-15
US9657008B2 (en) 2017-05-23
BR112015017331A2 (en) 2017-07-11
US20160137634A1 (en) 2016-05-19
AR094553A1 (en) 2015-08-12
CN104936953A (en) 2015-09-23
HK1214592A1 (en) 2016-07-29
MX2015009465A (en) 2015-09-28
BR112015017331A8 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
HK1222859A1 (en) Chemical compounds
HRP20180839T1 (en) Chemical entities
GB201304245D0 (en) Chemical compounds
GB201309085D0 (en) Compounds
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201310542D0 (en) Compounds
HK1214592A1 (en) Chemical compounds
GB201309508D0 (en) Compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
EP3010923A4 (en) Pyrroloquinazoline compounds
EP2948457A4 (en) Compounds
GB201306794D0 (en) Compounds
GB201322733D0 (en) Chemical compounds
GB201310460D0 (en) Compounds
GB201313885D0 (en) Chemical Compounds
GB201306881D0 (en) Chemical compounds
GB201310464D0 (en) Compounds
GB201310115D0 (en) Compounds
GB201310047D0 (en) Compounds
GB201309728D0 (en) Compounds
GB201309015D0 (en) Compounds
GB201308975D0 (en) Compounds
GB201308409D0 (en) Compounds
GB201307938D0 (en) Compounds